MetLife Investment Management LLC Has $1.87 Million Holdings in Envista Holdings Co. (NYSE:NVST)

MetLife Investment Management LLC raised its holdings in Envista Holdings Co. (NYSE:NVST) by 9.2% in the 4th quarter, HoldingsChannel reports. The firm owned 97,008 shares of the company’s stock after purchasing an additional 8,140 shares during the quarter. MetLife Investment Management LLC’s holdings in Envista were worth $1,871,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Franklin Resources Inc. increased its stake in shares of Envista by 72.6% in the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after buying an additional 2,882,844 shares in the last quarter. Norges Bank acquired a new stake in Envista in the 4th quarter valued at about $38,052,000. Dimensional Fund Advisors LP increased its position in Envista by 19.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock valued at $130,440,000 after acquiring an additional 1,089,923 shares in the last quarter. Pzena Investment Management LLC bought a new position in shares of Envista in the fourth quarter worth about $16,979,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Envista during the fourth quarter worth approximately $10,808,000.

Analysts Set New Price Targets

A number of analysts recently weighed in on NVST shares. Jefferies Financial Group raised their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. New Street Research set a $19.00 target price on Envista in a research report on Thursday, March 6th. JPMorgan Chase & Co. decreased their price target on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Finally, Bank of America reduced their target price on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Envista has an average rating of “Hold” and an average target price of $20.25.

Envista Price Performance

Shares of NVST stock opened at $16.21 on Wednesday. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -2.50, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. Envista Holdings Co. has a 12-month low of $14.22 and a 12-month high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The firm has a fifty day moving average of $17.00 and a 200-day moving average of $19.08.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities research analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.